抗人CD3单链抗体基因构建、表达及表达产物的分离、纯化和活性测定
摘要
CD3分子是成熟T淋巴细胞表面的一种分化抗原，与T细胞表面 受体(TCR)紧密结合构成TCR／CD3复合物，TCR识别和结合抗原后，通过CD3分子的信号转导系统，将刺激信号传入T淋巴细胞内部，激活酪氨酸激酶(PTK)及蛋白激酶c(PKC)，触发一系列级联效应及多种细胞因子的释放。最终导致T淋巴细胞的活化。抗CD3抗体具有丝裂原作用，可诱导T淋巴细胞的活化和增殖，一般认为是抗CD3抗体与CD3分子结合后，导致TCR／CD3复合物构型改变，并通过其它辅助细胞参与，引起
CD3 molecule is a differential antigen which is present on the surface of mature lymphocytes. The CD3 molecule exists as a TCR/ CD3 complex by tightly associated with T-cell receptor (TCR). When T- cell receptor binding and recognizing antigen, the signal is transducted into T cell through CD3 molecules, as a result of TCR / CD3 triggering, lead to release of cytokines and activate the T lymphocytes. Anti-CD3 McAbs may disrupt T cell by blocking and modutating the TCR and they strongly supress T cell-mediated responses by causing T cell depletion. The anti -CD3 McAb(OkT3) was first used as an immunosupresive agent in transplant recipients. It is also found that anti-CD3 McAbs have the ability to induce T lymphocytes activation and proliferation. There is a hypothesis that the anti-CD3 McAbs change the conformation of TCR/CD3 as they binding the CD3 moleucles, induce the release of
CD3 molecule is a differential antigen which is present on the surface of mature lymphocytes. The CD3 molecule exists as a TCR/ CD3 complex by tightly associated with T-cell receptor (TCR). When T- cell receptor binding and recognizing antigen, the signal is transducted into T cell through CD3 molecules, as a result of TCR / CD3 triggering, lead to release of cytokines and activate the T lymphocytes. Anti-CD3 McAbs may disrupt T cell by blocking and modutating the TCR and they strongly supress T cell-mediated responses by causing T cell depletion. The anti -CD3 McAb(OkT3) was first used as an immunosupresive agent in transplant recipients. It is also found that anti-CD3 McAbs have the ability to induce T lymphocytes activation and proliferation. There is a hypothesis that the anti-CD3 McAbs change the conformation of TCR/CD3 as they binding the CD3 moleucles, induce the release of
引文
1. Kohler G, Milstcin C.Coutinuous cultures off used cells secreting antibody of predefined specificity. Nature. 1975;256:495-497
1. Sharon J, Gefer ML, Morrison SL, et al. Expression of a VH / CK chimeric protein in mouse myloma cells. Nature. 1984;309:364-367
3. Ochi A, Hawley RG, Shulman MJ, et al. Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy chains into lymphoid cells. Nature.1983;302:340-342
4. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antiobdy molecules: mouse antigen—binding domains with human constant region domains . Proc Natl Acad Sci USA. 1984;81:6851-6855
5. Bollianne GL, Hozumi N, Shulman MJ. Production of functional chimeric mouse/human antibody. Nature. 1984;312:643-646
6. Sahagan BG, Dorai H, Saltzgaber- Muller J, et al. A genetically engineered murine / human chimeric antibody retains specificity of human tumor-associated antigen. J Immunol. 1986;137:1066-1074
7. Sun LK, Curtis P, Rakowicz-Szulczynska E, et al. Chimeric antibody with human constant regions and mouse variable regions directed against caricinoma—associated antigen 17-1A. Proc Natl Acad Sci USA. 1987; 84:214-218
8. Steplewski Z, Su LK, Shearman J, et al. Biological activity of human -mouse IgG1, IgG2, IgG3 and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA. 1988;85;4852-4856
9. Lobugio AF, Wheeler RH, Trang J, et al. Mouse / human chimeric McAb in man : kinetice and immunce response. Proc Natl Acad Sci USA. 1989; 85: 4220-4224
10. Hutzell P, kashmiri S, Colcher D, et al. Generation and characterization of a recombinant chimeric B72.3. Cancer Res. 1991; 51:181-189
11. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti- GD2 monoclonal antiobdy chl4. 18 in patients with malignant melanoma. Hum Antibody Hybri. 1992;3:19-24
12. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse- human chimeric anti- TNF antibody. Mol Immunol. 1993;30:1443-1453
13. Poul MA, CeruttiM, Chaubihi H, et al. Cassette taculovirus vectors for the production of chimeric humanizaed or human antibodies in insect cells. Eur J Immunol. 1995;25(7):2005-2009
14. Evans MJ, Hartman SL, Wolff DW, et al. Rapid expression of an anti-human C5 chimeric Fab untilizing a vector that replicates in cos and293 cells. J Immunol Methods. 1995;184(1):123-138
15. Jin BR, Ryn CJ, Kang SK, et al. Characterization of a murine-human chimeric antibody with specificity of the pre- S2 surface antigen of hepatitis B virus, expressed in baculovirus- infected insect cells. Virus Res. 1995;38(2):269-277
16. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor ( CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation. 1995;60(7):748-756
17. Allegre ML, Tso JY, Sattar HA, et al. An anti- murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol. 1995;155(3):1544-1555
18. Liu AY, Robinson RR, Hellstron KE, et al. Chimeric mouse- human IgG1 antiody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA. 1987;84:3439-3493
19. Larrick JW, Danielsson L, Brenner CA, et al. Polymerase chain reaction using mixed primers: cloning of human monolconal antibody variable region genes from single hybridoma cells. Biotechnolgy. 1989;7:934-939
20. Orlandi R, Gussow DH, Jones PT and Winter G. Cloning immunoglobin variable domains for expression by the polymerasc chain reaction. Proc Natl Acad Sci USA. 1989;86:3833-3837
21. Persson MA, Caothien RH and Burton DR. Generation of diverse high offinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci USA. 1991;88:2432-2436
22. Mark JD, Tristem M, Karpas A and Winter G. Oligonuclcotide primers for polymcrase chain reaction amplification of human immunogiobulin variable genes and design of family-spccific oligonuclcotidc pcimcrs. Eur J Immunol. 1991;21:985-991
23. Caton A and Koprowski H. Influenza virus hemagglutinin-specific antibodies isolated form a combinantorial expression library are closely related to the immune response of the donor. Proc Natl Acad Sci USA. 1990;87:6450-6454
24．杨安钢，许辉，吉昌华等．抗人CD3单抗重，轻链可变区基因的体外扩增，克隆和序列分析．生物化学杂志1994；10(2)：213-217
25．韩骅，杨立宏，药立波等．人黑色素瘤特异性单克隆抗体可变区基因的克隆和序列测定．第四军医大学学报．1993；14(1)：1-4
26. Moreland LW, Pratt PW, Maycs MD, et al. Double-bind placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, CM-T412 in rheumertoid arthritis patients receiving concomitant methotrexate. Arthritis and Rheumatism. 1995:38(11):1581-1588
27. Vandullemen HM, Vandeventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti- tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology.l995;109(l):129-135
28. CoMo and Queen C. Humanized antibodies for therapy. Nautre.l991;351:501-502
29. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity -determinig regions in a human antibody with those form a mouse. Nature. 1986;321:522—525
30. Verhoeyen M, Milstein C, Winter G, et al. Reshaping human antibodies: grafting an anti-lysozyme activity. Science. 1988;239:1534—1536
31. Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for hterapy. Nature. 1988;332:323-327
32. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin-2 receptor. Proc Natl Acad Sci USA. 1989; 86:10029-10033
33. Carter P, Presta L, Gorman CM, et al. Humanization of an anti- p185HER2 antibody for human. Proc Natl Acad Sci.1992;89:4285-4289
34. Singer II, Kawka DW, DeMartino JA, et al. Optimal humanization of 1B4, and anti—CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framwork sequences. J Immunol. 1993;150:2844-2857
35. Stephens S, Emtage S, Vetterlein O, et al. Comprehensive pharmacokinetics of humanized antibody and analysis of residual anti -idiotypic responses. Immunology. 1995;85(4):558-574
36. Co M, Deshamps M, Whitely R and Queen C. Humanized antibodies for antiviral therapy. Proc Natl Acad Sci USA. 1991;88:2869-3873
37. Tempest PR, Barbanti E, Bremner P, et al. A humanized anti- tumor necrosis factor—a monoclonal antibody that acts as a partial competive antagonist of the template antibody. Hybridoma 1994;13:183-190
38. Tramontano A, Chothia C and Lesk AM. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol. 1990;215:175-185
39. Xiang J, Zha YH, Jia ZC, et al. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformaiton of heavy-chain hypervariable loops. J Mol Biol. 1995;253(3):385-390
40. Daugherty BL, DeMartino JA, LawMF, et al. Polymerase chain reaction facilitates the cloning: CDR grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res. 1991;19:2471-2476
41. Poul MA, Cerutti M, Chaubihi H, et al. Cassette baculovirus vectors of the production of chimeric humanized or human antibodies in insect cells. Eur J Immunol. 1995;25(7):2005-2009
42. Evans MJ, Hartman SL, Wolff DW, et al. Rapid expression of an anti -human C5 chimeric Fab utilizing a vector that replicates in COS and293 cells. J Immunol Methods. 195;184(1): 123-138
43. Jin BR, Ryn CJ, Kang SK, et al. Characterization of a murine-human chimeric antibody with specificity for the pre- s2 surface antigen of hepatitis B viurs, expressed in baculovirus- infected insect cells. Virus Research. 1995;38:269-277
44. Cabilly S, Riggs AD, Pande H, et al. Generation of antibody activity from immunoglobulin polypetide chains produced in Escherichia coli. Proc Natl Acad Sci USA. 1984;81:3273-3277
45. Better M, Chang CP, Robinson RR, et al. Escherichia coli secretion of an active chimeric antibody fragment. Science. 1988;240:1041-1043
46. Chang CN, Landolfi NF, Queen C, et al. Expression of antibody Fab domains on phage surfaces potential use for antibody selection. J Immunol.1991;147:3610-3614
47. Skerra A and Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coll. Science. 1988;240:1038-1041
48. Ricchmann L, Foote J and Winter G. Expression of an antibody Fv fragment in myeloma cells. J Mol Biol. 1988;203:825-828
49. Glockshuber R, Malia M, Pfityinger I and pluckthun A. A comparison of strate-gies to stabilize imm unoglobulin Fv-fragrnents. Biochemistry. 1990;29:1362-1367
50. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science. 1988;242:423-426
51. Huston.JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antiobdy binding sites: recovery of specific activity in an anti -digoxin single—chain Fry analogue produced in Escherichia coli. Proc Natl Acad Sci USA. 1988;85:5879-5883
52. Ladner RC. US Patent. 1987;No 4702, 692
53. Pantoliono MW, Bird RE, Johnson S, et al. Conformational stability, folding and ligand-binding affinity of single chain Fv immunoglobulin,fragment expressed in Escherichia coli. Biochemistry 1991;30:10117-10125.
54. Batra JK, FitzGerald D, Gately M, et al. Anti-Tac(Fv)-PE40, a single chain antibody pseudomenas fusion protein directed at interleukin-2 receptor bearing cells. J Biol Chem. 1990;265:15198-15202
55. C4haudhary VK, Bartra JK, Gallo MG, et al. A rapid methods of cloning functional variable-region antibody genes in Escherichia coli as single-chainimmunotoxins. Proc Natl Acad Sci USA. 1990;87:10:55-1070
56. Davis GT, Bedzyk WD, Voss EV and Jacobs TW. Single chain antibody(SCA) encoding genes: one-step construction and expression in eukaryotic cells Bio/technology. 1991;9:165-169
57. Gibbs RA, Posner BA, Filpula DR, et al. Construction and characterization of a single-chain catalytic antibody. Proc Natl Acad Sci USA. 1991;88:4001-4004
58. Huston JS, Mudgett-Hunter M, Tai MS, et al. Protein engineering of single-chain Fv analogs and fusion proteins. Methods Euzymol. 1991; 203:45-50
59. Barry MM and Lee JS. Cloning and expression of an autoimmune DNA -binding single chain Fv only the heavy chain is required fro binding . Mol Immunol. 1993;30(9):833-840
60. Foryen G, Ronsse I and Billiau A. Bacterial expression of a single -chain antibody fragment ( scFv) that neutralizes the biological activity of human interferon—γ. Mol Immunol. 1993;30(9):805-812
61. Laukkanen ML, Alfthan K and Keinanen K. Functional immunoliposomes harboring a bio-synthetically lipid- tagged single chain antibody. Biochemistry. 1994;33(38):11664-11670
62. Anand NN, Mandal S. Mackenzie CR, et al. Bacterial expression and secretion of various single-chain Fv genes encoding proteins specific for a salmonella serotype B O-antigen. J Biol Chem. 1991;266(32): 21874-21879
63. Ayala M, Balint RF, Fernandezdecossio ME, et al. Variable region sequences modulates periplasmic export of a single- chain Fv antibody frgment in Escherichia coli. Biotechniques. 1995;18(15):832—838
64. McCafferty J, Griffiths AD, Winter G, et al. Phage antibodies: bilamentous phage antibody variable doamins. Nature.1990;348:552-554
65. Piccioli P, Diluzio A, Amann R, et al. Neuro- antibodies: Ectopic expression of a recombinant anti-substance P antibody in the central nervous system of transgenic mice . Neuron. 1995;15(2):373—384
66. Fiedlor U and Conrad U. High-Level production and long-term storage of engineered antibodies in transgenic tabacco seeds. Bio— Technology.1995;13(10):1090-1093
67. Milenic DE, Yokota T, Filpula DR, et al. Construction,binding properities, metabolism, and tumor targeting of a single— chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991;51:6363-6371
68. Kippiyanov SM, Dubel S, Breitling F, et al. Recombinant single- chain Fv fragments carrying C- terminal systeine residues: production of bivalent and bioinylation miniantibodies. Mol Immunol. 1994; 31( 14) :1047-1058
69. Cumber AJ, Ward ES, Winter G, et al. Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bis Fv Cys fragment and a bis Fv Cys conjugate. J Immunol. 1992;149:120—126
70. Pack P and Rluckthun A. Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry. 1992;31(6):1579-1584
71. George ATT, Jamar F, Tai MS, et al. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Technetium -99m coordination by single—chain Fv antibody fusion proteins through a C-terminaJ cysteinyl peptide. Proc Natl Acad Sci USA. 1995;92(18): 8358-8362
72. Jiang W, VenugopalK, Gould EA, et al. Intracellular interference of tick-borne flavivirus infection by using a single- chain antibody fragment delivered by recombinant Sindbis virus. J Virol. 1995;69( 2) :1044-1049
73. Maciejewski JP, Weichold FF, Young NS, et al. Intracellular expression of antibody fragments directed against HIV reverse tanscriptase prevents HIV infection in vitro. Nature Medicine. 1995;1(7):667—673
74. Duan L, Bagasra O, Laughlin MA, et al. Potent inhibition of human immunodeficiency virus type I replication by an intracellular anti- Rev single-chain antibody. Proc Natl Acad Sci USA. 1994;91(11):5075-5079
75. Wels W, Moritz D, Schmidt M, et al. Biotechnological and gene therapeutic trategies in cancer treatment. Gene. 1995;159(1):73-80
76. Kontermann RE, Liu ZH, Schulze RA, et al. Characterization of the epitope recognized by a monoclonal antibody directed against the largest Subunit of Drosophila RNA polymerase II .Biol Chem Hoppe-Seyler. 1995;376(8):473-481
77. Molloy P, Brydon L. Porter AJ, et al. Separation and concentration of bacteria with immobilized antibody fragments. J App Bacteriology. 1995 ;78(4):359-365
78. Newsted WJ, Ramjeesingh M, Zywulko M, et al. Engineering resistance to trypsin inactivation into L- asparaginase through the productor of a chimeric protein between the enzyme and a protective single—chain antibody. Enzyme Microbiol Technolgy. 1995;17(8):757-764
79. Ward ES, Gussow D, Griffths et al. Binding of a repertorie of single immunoglobulin variable domains secreted from Eshcerichia coli. Nature. 1989;341:544-546
80. Williams WV, Moss DA, Kieber- Emmons T, et al. Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci USA. 1989;86:5537-5541
81. Holliger P, Prospero T and Winter G. "Diabodies" small bivalent and bispecific antibody framgents. Proc Natl Acad Sci USA. 1993; 90: 6444 -6448
82. Cruber M, Schodin BA, Wilson ER, et al. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol. 1990;152:5368-5374
83. Mallender WD and Voss J EW. Construction, expression and activity of a vivalent bispecific single-chain antibody. J Biol Chem. 1994;269(l):199-206
84. Choe M, Webber KO and Pastan I. B3(Fab) - pE38: a recombinant immunotoxin in which a mutant form of pseudomonas extoxin in fused to the Fab fragment of monoclonal antibody B3. Cancer Res. 1994; 54: 3460-3467
85. Wels W, Beerli R, Hellmann P, et al. EGF receptor and pl85 erbB- 2 -specific single-chain antibody toxins differ in their cell- killing activity on tumor cells expressing both receptor proteins. Int J Cancer. 1995;60:137—144
86. Benhar I, Reiter Y, Pai LH, et al. Administration of disulfide -stabilized Fv-immunotoxins B3 (dsFv) - pE38 and B3( dsFv) - pE38 by contnuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int J Cancer. 1995;62:351-355
87. Gillies SD, Reilly EB, Lo KM, et al. Antiobdy-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA. 1992;89:1428-1432
88. Yang JB, Moyana T and Xiang J. A gentically engineered single— chain Fv / TNF molecule possesses the actitumor immuno—reactivity of Fv as well as the cytotoxic activity of tumor necrosis factor. Mol Immunol. 1995;32d(12):873-881
89. Rei R, Schlom J, Kashmivi SVS. Baculovirus expression of a functional single-chain immuno-globulin and its IL-2 fusion protein. J Immunol. Methods. 1995;186(2):245-255
90. Tramontano A, Tanda kD and Lerner RA. Catalytic antibodies. Science. 1986;234:1566-1570
91. Lerner RA, Berkovic SJ and Schultz PG. At the crossroads of chemistry and immunology: catalytic antibodies. Science. 1991; 252: 659 -667
92. Haynes MR, Stura EA, Hilvert D, et al. Routes to catalysis: structure of catalytic antibody and comparison with its natural conterpart. Science. 1994;263:646-
93. Robert VA, Ivevson BL, Ivevson SA, et al. Antibody remodeling: a general solution to the design of of metal— coordination site in an antibody—binding pocket. Proc Natl Acad Sci USA. 1990;87:6654-6658
94. Baldwin E, Schultz PG. Generation of a catalytic antibody by site -directed mutagenesis. Science. 1989;245:1104-1107
95. Smiloy JA and Benkovic SJ. Selection of catalytic antibodies for a biosynthetic reaction from a combinatorial cDNA library by complementation of an auxotrophic Escherichia coli: antibodies for orotate decarboxylation. Proc Natl Acad Sci USA. 1994;91:8319-8323
96. Wentworkth P, Datta A, BlakeyD, et al. Towrad antibody-directed "abzyme" prodrug therapy ADAPT: carbamate prodrug activition by a catalytic antiboddy and tis in vitro application to human tumor cell killing. Proc Natl Acad Scid USA. 1996;93(2):799-803
97. HuseWD, Sastry L, Iverson SA, et al. Generation of a large combinational library of the immunoglobulin repertoire in phage lambda. Science. 1989;246:1275-1281
98. Marks JD, Griffiths AD, MaimqvistM, et al. By-passing immunization: building high affinity human antibodies by chain shuffling. Bio / Technology. 1992;10:779-783
99. Cai XH and Garen A. Anti—melanoma antiobdies form melanoma patients immunized with genetically modified antibodies form single— chain Fv fusion phage libravies. Proc Natl Acad Sci USA. 1995;92(14):6537-6541
100. Marks JD, Hoogenboom HR, Bonnert TP, et al. By-passing immunization: human antibodies from V—gene libraries displayed on phage. J Mol Biol. 1991;222:581-597
101. Barbas CF, Kang AS, Lerner RA, et al. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA. 1991;88:7978-7982
102. Kung PC, Goldstein G. Monoclonal antibodies defining distinctive human T cell surface antigens. Science. 1979;206:347-349
103. Van Vauwe JP, DeMey JR and Goossens JD. OKT3 a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol. 1980;124:2708-2713
104. Yun YS, Hargrove ME and Ting C. Hetero-geneity of long-term culture acti- vated killer cells induced by anti-CD3 antibody. J Immunol. 1988;141:1390—1397
105. Weiss A, Imboden J, HArdyK, et al.Annu Rev Immunol. 1986;4:593
106. Nishizuka Y. Science. 1986;4:593
107. Patel MP, Samclson LE and Klausuer RD. Multiple kinases and signal transduction. J Biol Chem. 1987;262:5831-3838
108. Samelson LE, Phillips AF, Lnong ET, et al. Proc Natl Acad Sci USA. 1990;87:4358
109. Boyer C, Auphan N, Luton F, et al. T cell receptor/ CD3 complex internalization following activation of a cytolytic T cell clone: evidence for a protein kinase C-independent staurosporine—sensitive step. Eur J Immunol. 1991;21:1623-1634
110. De Jong R, Brouwer M, Rebel VI, et al. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirments for human cytolytic T- lymphocyte differentiation. Immunol. 1990;70:357-364
111. Gromo G, Geller RL, Inverardi L, et al. Signal reguirements in the step—wise functional maturation of cytotoxic T lymphocytes. Nature. 1987;327:434-436
112. Takai Y, Herrmann SH, Greenstein JL, et al. Requirement of three distinct lymphokines for the induction of cytotoxic T lymphocytes from thymocytes. J Immunol. 1986;137:3494-3500
113. Jung G, Martin DE and Muller—Eberhard HJ. Induction of cytotoxicity in hu- man peripheral blood mononulear cells by monoclonal antibody OKT3. J Immunol. 1987;139:639-644
114. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft regection with OKT3 monoclonal antibody. Transplantation. 1981;32:535—539
115. Hirsch RM, Eckhclonal H, Auchincloss DH, et al. Effects of in vivo admini- stration of anti-T3 monoclonal antibody on T cell function in mice:I.Immunosupression of transplantation response. J Immuno 1988; 140:3766-3772
116. Segal DM, Garrido MA, Prez P, et al. Targeted cytotoxic cells as a novel form of cancer immunotherapy. Mol. Immunol. 1988;25:1099—1103
117. Nitta T, Sato K, yagita H et al. Preliminary trail of specific targeting therapy against malignant glioma. Lancet 1990;335:368—371
118. Perez P, Hoffman RW, Shaw S, et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985;316:354-356
119. VanDijk JSO, Warnaar JDH, Van Eendenbury M, et al. Induction of tumor—cell lysis by bi- specific antibodies recognizing renal— cell carcinoma and CD3 antigen. Int J Cancer 1989;43:344-351
120. Parren PWHI, Warmerdam PAM. Boeije LCM, et al. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. J Immunol. 1992;148:695—701
121. Shalaby MR, Shepard HM, Presta L, et al. Development of humanized bispecific antibodies reactive overexpressing the HER2 protooncogene. J Exp Med. 1992;175;217-225
122. Rodrigues ML, Shalaby MR, Werther W, et al. Engineering a humanized bispecific F(ab')2 P fragment for improved binding to T cells. Int J Cancer. 1992;7:45-56
123. Chamow SM, Zhang DZ. Tang XY, et al. A humanized, bispecific immunodhcsin-antibody that retargets CD3+ effcctors to kill HIV-1-infected cells. J Immunol. 1994;153:4268-4280
124. Allegre ML, Tso Jy, Sattar HA, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol. 1995;155(3): 1544-1555
125. Mu SL, Thompson J, Hu HZ, et al. Expression and characterization of a bivalent chimeric anti-human CD3 single chain antibody. Sacadinvian J Immunol. 1996;43:134-139
126. Horton RM, Hunt HD. Ho SN, et al. Engineering bybrid genes withoutthe use of restriction enzymes: gene splicing by overlap extension. Gene. 1988;77:61-68
127. Laemmli Uk. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685
128．高磊．两株人源性HFRSV单抗可变区基因的克隆、序列分析及表达的研究．博士论文1994
129．胡川闽．抗肝癌单链免疫毒素的基因构建、及其导向作用的实验研究．博士论文1996
130. Marston FAO. The purification of eukaryotic polypcptcdcs synthesized in Eschcrichia coll. Biochemistry J 1986;240: 1-12
131. Chapoval AI, Nelson H, Thibault C, ctal. Anti-Cd3×anti-tumor F(ab′)2bisfunctional antibody activates and rctargcts tumor-infiltrating lym phocytcs. J Immunol 1995; 155(3): 1296-13031
132．韩丽英．抗金属螯合四肽单克隆抗体可变区基因的构建及表达．博士论文，1995
1. Sharon J, Gefer ML, Morrison SL, et al. Expression of a VH / CK chimeric protein in mouse myloma cells. Nature. 1984;309:364-367
3. Ochi A, Hawley RG, Shulman MJ, et al. Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy chains into lymphoid cells. Nature.1983;302:340-342
4. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antiobdy molecules: mouse antigen—binding domains with human constant region domains . Proc Natl Acad Sci USA. 1984;81:6851-6855
5. Bollianne GL, Hozumi N, Shulman MJ. Production of functional chimeric mouse/human antibody. Nature. 1984;312:643-646
6. Sahagan BG, Dorai H, Saltzgaber- Muller J, et al. A genetically engineered murine / human chimeric antibody retains specificity of human tumor-associated antigen. J Immunol. 1986;137:1066-1074
7. Sun LK, Curtis P, Rakowicz-Szulczynska E, et al. Chimeric antibody with human constant regions and mouse variable regions directed against caricinoma—associated antigen 17-1A. Proc Natl Acad Sci USA. 1987; 84:214-218
8. Steplewski Z, Su LK, Shearman J, et al. Biological activity of human -mouse IgG1, IgG2, IgG3 and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA. 1988;85;4852-4856
9. Lobugio AF, Wheeler RH, Trang J, et al. Mouse / human chimeric McAb in man : kinetice and immunce response. Proc Natl Acad Sci USA. 1989; 85: 4220-4224
10. Hutzell P, kashmiri S, Colcher D, et al. Generation and characterization of a recombinant chimeric B72.3. Cancer Res. 1991; 51:181-189
11. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti- GD2 monoclonal antiobdy chl4. 18 in patients with malignant melanoma. Hum Antibody Hybri. 1992;3:19-24
12. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse- human chimeric anti- TNF antibody. Mol Immunol. 1993;30:1443-1453
13. Poul MA, CeruttiM, Chaubihi H, et al. Cassette taculovirus vectors for the production of chimeric humanizaed or human antibodies in insect cells. Eur J Immunol. 1995;25(7):2005-2009
14. Evans MJ, Hartman SL, Wolff DW, et al. Rapid expression of an anti-human C5 chimeric Fab untilizing a vector that replicates in cos and293 cells. J Immunol Methods. 1995;184(1):123-138
15. Jin BR, Ryn CJ, Kang SK, et al. Characterization of a murine-human chimeric antibody with specificity of the pre- S2 surface antigen of hepatitis B virus, expressed in baculovirus- infected insect cells. Virus Res. 1995;38(2):269-277
16. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor ( CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation. 1995;60(7):748-756
17. Allegre ML, Tso JY, Sattar HA, et al. An anti- murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol. 1995;155(3):1544-1555
18. Liu AY, Robinson RR, Hellstron KE, et al. Chimeric mouse- human IgG1 antiody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA. 1987;84:3439-3493
19. Larrick JW, Danielsson L, Brenner CA, et al. Polymerase chain reaction using mixed primers: cloning of human monolconal antibody variable region genes from single hybridoma cells. Biotechnolgy. 1989;7:934-939
20. Orlandi R, Gussow DH, Jones PT and Winter G. Cloning immunoglobin variable domains for expression by the polymerasc chain reaction. Proc Natl Acad Sci USA. 1989;86:3833-3837
21. Persson MA, Caothien RH and Burton DR. Generation of diverse high offinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci USA. 1991;88:2432-2436
22. Mark JD, Tristem M, Karpas A and Winter G. Oligonuclcotide primers for polymcrase chain reaction amplification of human immunogiobulin variable genes and design of family-spccific oligonuclcotidc pcimcrs. Eur J Immunol. 1991;21:985-991
23. Caton A and Koprowski H. Influenza virus hemagglutinin-specific antibodies isolated form a combinantorial expression library are closely related to the immune response of the donor. Proc Natl Acad Sci USA. 1990;87:6450-6454
24．杨安钢，许辉，吉昌华等．抗人CD3单抗重，轻链可变区基因的体外扩增，克隆和序列分析．生物化学杂志1994；10(2)：213-217
25．韩骅，杨立宏，药立波等．人黑色素瘤特异性单克隆抗体可变区基因的克隆和序列测定．第四军医大学学报．1993；14(1)：1-4
26. Moreland LW, Pratt PW, Maycs MD, et al. Double-bind placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, CM-T412 in rheumertoid arthritis patients receiving concomitant methotrexate. Arthritis and Rheumatism. 1995:38(11):1581-1588
27. Vandullemen HM, Vandeventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti- tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology.l995;109(l):129-135
28. CoMo and Queen C. Humanized antibodies for therapy. Nautre.l991;351:501-502
29. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity -determinig regions in a human antibody with those form a mouse. Nature. 1986;321:522—525
30. Verhoeyen M, Milstein C, Winter G, et al. Reshaping human antibodies: grafting an anti-lysozyme activity. Science. 1988;239:1534—1536
31. Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for hterapy. Nature. 1988;332:323-327
32. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin-2 receptor. Proc Natl Acad Sci USA. 1989; 86:10029-10033
33. Carter P, Presta L, Gorman CM, et al. Humanization of an anti- p185HER2 antibody for human. Proc Natl Acad Sci.1992;89:4285-4289
34. Singer II, Kawka DW, DeMartino JA, et al. Optimal humanization of 1B4, and anti—CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framwork sequences. J Immunol. 1993;150:2844-2857
35. Stephens S, Emtage S, Vetterlein O, et al. Comprehensive pharmacokinetics of humanized antibody and analysis of residual anti -idiotypic responses. Immunology. 1995;85(4):558-574
36. Co M, Deshamps M, Whitely R and Queen C. Humanized antibodies for antiviral therapy. Proc Natl Acad Sci USA. 1991;88:2869-3873
37. Tempest PR, Barbanti E, Bremner P, et al. A humanized anti- tumor necrosis factor—a monoclonal antibody that acts as a partial competive antagonist of the template antibody. Hybridoma 1994;13:183-190
38. Tramontano A, Chothia C and Lesk AM. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol. 1990;215:175-185
39. Xiang J, Zha YH, Jia ZC, et al. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformaiton of heavy-chain hypervariable loops. J Mol Biol. 1995;253(3):385-390
40. Daugherty BL, DeMartino JA, LawMF, et al. Polymerase chain reaction facilitates the cloning: CDR grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins. Nucleic Acids Res. 1991;19:2471-2476
41. Poul MA, Cerutti M, Chaubihi H, et al. Cassette baculovirus vectors of the production of chimeric humanized or human antibodies in insect cells. Eur J Immunol. 1995;25(7):2005-2009
42. Evans MJ, Hartman SL, Wolff DW, et al. Rapid expression of an anti -human C5 chimeric Fab utilizing a vector that replicates in COS and293 cells. J Immunol Methods. 195;184(1): 123-138
43. Jin BR, Ryn CJ, Kang SK, et al. Characterization of a murine-human chimeric antibody with specificity for the pre- s2 surface antigen of hepatitis B viurs, expressed in baculovirus- infected insect cells. Virus Research. 1995;38:269-277
44. Cabilly S, Riggs AD, Pande H, et al. Generation of antibody activity from immunoglobulin polypetide chains produced in Escherichia coli. Proc Natl Acad Sci USA. 1984;81:3273-3277
45. Better M, Chang CP, Robinson RR, et al. Escherichia coli secretion of an active chimeric antibody fragment. Science. 1988;240:1041-1043
46. Chang CN, Landolfi NF, Queen C, et al. Expression of antibody Fab domains on phage surfaces potential use for antibody selection. J Immunol.1991;147:3610-3614
47. Skerra A and Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coll. Science. 1988;240:1038-1041
48. Ricchmann L, Foote J and Winter G. Expression of an antibody Fv fragment in myeloma cells. J Mol Biol. 1988;203:825-828
49. Glockshuber R, Malia M, Pfityinger I and pluckthun A. A comparison of strate-gies to stabilize imm unoglobulin Fv-fragrnents. Biochemistry. 1990;29:1362-1367
50. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science. 1988;242:423-426
51. Huston.JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antiobdy binding sites: recovery of specific activity in an anti -digoxin single—chain Fry analogue produced in Escherichia coli. Proc Natl Acad Sci USA. 1988;85:5879-5883
52. Ladner RC. US Patent. 1987;No 4702, 692
53. Pantoliono MW, Bird RE, Johnson S, et al. Conformational stability, folding and ligand-binding affinity of single chain Fv immunoglobulin,fragment expressed in Escherichia coli. Biochemistry 1991;30:10117-10125.
54. Batra JK, FitzGerald D, Gately M, et al. Anti-Tac(Fv)-PE40, a single chain antibody pseudomenas fusion protein directed at interleukin-2 receptor bearing cells. J Biol Chem. 1990;265:15198-15202
55. C4haudhary VK, Bartra JK, Gallo MG, et al. A rapid methods of cloning functional variable-region antibody genes in Escherichia coli as single-chainimmunotoxins. Proc Natl Acad Sci USA. 1990;87:10:55-1070
56. Davis GT, Bedzyk WD, Voss EV and Jacobs TW. Single chain antibody(SCA) encoding genes: one-step construction and expression in eukaryotic cells Bio/technology. 1991;9:165-169
57. Gibbs RA, Posner BA, Filpula DR, et al. Construction and characterization of a single-chain catalytic antibody. Proc Natl Acad Sci USA. 1991;88:4001-4004
58. Huston JS, Mudgett-Hunter M, Tai MS, et al. Protein engineering of single-chain Fv analogs and fusion proteins. Methods Euzymol. 1991; 203:45-50
59. Barry MM and Lee JS. Cloning and expression of an autoimmune DNA -binding single chain Fv only the heavy chain is required fro binding . Mol Immunol. 1993;30(9):833-840
60. Foryen G, Ronsse I and Billiau A. Bacterial expression of a single -chain antibody fragment ( scFv) that neutralizes the biological activity of human interferon—γ. Mol Immunol. 1993;30(9):805-812
61. Laukkanen ML, Alfthan K and Keinanen K. Functional immunoliposomes harboring a bio-synthetically lipid- tagged single chain antibody. Biochemistry. 1994;33(38):11664-11670
62. Anand NN, Mandal S. Mackenzie CR, et al. Bacterial expression and secretion of various single-chain Fv genes encoding proteins specific for a salmonella serotype B O-antigen. J Biol Chem. 1991;266(32): 21874-21879
63. Ayala M, Balint RF, Fernandezdecossio ME, et al. Variable region sequences modulates periplasmic export of a single- chain Fv antibody frgment in Escherichia coli. Biotechniques. 1995;18(15):832—838
64. McCafferty J, Griffiths AD, Winter G, et al. Phage antibodies: bilamentous phage antibody variable doamins. Nature.1990;348:552-554
65. Piccioli P, Diluzio A, Amann R, et al. Neuro- antibodies: Ectopic expression of a recombinant anti-substance P antibody in the central nervous system of transgenic mice . Neuron. 1995;15(2):373—384
66. Fiedlor U and Conrad U. High-Level production and long-term storage of engineered antibodies in transgenic tabacco seeds. Bio— Technology.1995;13(10):1090-1093
67. Milenic DE, Yokota T, Filpula DR, et al. Construction,binding properities, metabolism, and tumor targeting of a single— chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991;51:6363-6371
68. Kippiyanov SM, Dubel S, Breitling F, et al. Recombinant single- chain Fv fragments carrying C- terminal systeine residues: production of bivalent and bioinylation miniantibodies. Mol Immunol. 1994; 31( 14) :1047-1058
69. Cumber AJ, Ward ES, Winter G, et al. Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bis Fv Cys fragment and a bis Fv Cys conjugate. J Immunol. 1992;149:120—126
70. Pack P and Rluckthun A. Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry. 1992;31(6):1579-1584
71. George ATT, Jamar F, Tai MS, et al. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Technetium -99m coordination by single—chain Fv antibody fusion proteins through a C-terminaJ cysteinyl peptide. Proc Natl Acad Sci USA. 1995;92(18): 8358-8362
72. Jiang W, VenugopalK, Gould EA, et al. Intracellular interference of tick-borne flavivirus infection by using a single- chain antibody fragment delivered by recombinant Sindbis virus. J Virol. 1995;69( 2) :1044-1049
73. Maciejewski JP, Weichold FF, Young NS, et al. Intracellular expression of antibody fragments directed against HIV reverse tanscriptase prevents HIV infection in vitro. Nature Medicine. 1995;1(7):667—673
74. Duan L, Bagasra O, Laughlin MA, et al. Potent inhibition of human immunodeficiency virus type I replication by an intracellular anti- Rev single-chain antibody. Proc Natl Acad Sci USA. 1994;91(11):5075-5079
75. Wels W, Moritz D, Schmidt M, et al. Biotechnological and gene therapeutic trategies in cancer treatment. Gene. 1995;159(1):73-80
76. Kontermann RE, Liu ZH, Schulze RA, et al. Characterization of the epitope recognized by a monoclonal antibody directed against the largest Subunit of Drosophila RNA polymerase II .Biol Chem Hoppe-Seyler. 1995;376(8):473-481
77. Molloy P, Brydon L. Porter AJ, et al. Separation and concentration of bacteria with immobilized antibody fragments. J App Bacteriology. 1995 ;78(4):359-365
78. Newsted WJ, Ramjeesingh M, Zywulko M, et al. Engineering resistance to trypsin inactivation into L- asparaginase through the productor of a chimeric protein between the enzyme and a protective single—chain antibody. Enzyme Microbiol Technolgy. 1995;17(8):757-764
79. Ward ES, Gussow D, Griffths et al. Binding of a repertorie of single immunoglobulin variable domains secreted from Eshcerichia coli. Nature. 1989;341:544-546
80. Williams WV, Moss DA, Kieber- Emmons T, et al. Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci USA. 1989;86:5537-5541
81. Holliger P, Prospero T and Winter G. "Diabodies" small bivalent and bispecific antibody framgents. Proc Natl Acad Sci USA. 1993; 90: 6444 -6448
82. Cruber M, Schodin BA, Wilson ER, et al. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol. 1990;152:5368-5374
83. Mallender WD and Voss J EW. Construction, expression and activity of a vivalent bispecific single-chain antibody. J Biol Chem. 1994;269(l):199-206
84. Choe M, Webber KO and Pastan I. B3(Fab) - pE38: a recombinant immunotoxin in which a mutant form of pseudomonas extoxin in fused to the Fab fragment of monoclonal antibody B3. Cancer Res. 1994; 54: 3460-3467
85. Wels W, Beerli R, Hellmann P, et al. EGF receptor and pl85 erbB- 2 -specific single-chain antibody toxins differ in their cell- killing activity on tumor cells expressing both receptor proteins. Int J Cancer. 1995;60:137—144
86. Benhar I, Reiter Y, Pai LH, et al. Administration of disulfide -stabilized Fv-immunotoxins B3 (dsFv) - pE38 and B3( dsFv) - pE38 by contnuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int J Cancer. 1995;62:351-355
87. Gillies SD, Reilly EB, Lo KM, et al. Antiobdy-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA. 1992;89:1428-1432
88. Yang JB, Moyana T and Xiang J. A gentically engineered single— chain Fv / TNF molecule possesses the actitumor immuno—reactivity of Fv as well as the cytotoxic activity of tumor necrosis factor. Mol Immunol. 1995;32d(12):873-881
89. Rei R, Schlom J, Kashmivi SVS. Baculovirus expression of a functional single-chain immuno-globulin and its IL-2 fusion protein. J Immunol. Methods. 1995;186(2):245-255
90. Tramontano A, Tanda kD and Lerner RA. Catalytic antibodies. Science. 1986;234:1566-1570
91. Lerner RA, Berkovic SJ and Schultz PG. At the crossroads of chemistry and immunology: catalytic antibodies. Science. 1991; 252: 659 -667
92. Haynes MR, Stura EA, Hilvert D, et al. Routes to catalysis: structure of catalytic antibody and comparison with its natural conterpart. Science. 1994;263:646-
93. Robert VA, Ivevson BL, Ivevson SA, et al. Antibody remodeling: a general solution to the design of of metal— coordination site in an antibody—binding pocket. Proc Natl Acad Sci USA. 1990;87:6654-6658
94. Baldwin E, Schultz PG. Generation of a catalytic antibody by site -directed mutagenesis. Science. 1989;245:1104-1107
95. Smiloy JA and Benkovic SJ. Selection of catalytic antibodies for a biosynthetic reaction from a combinatorial cDNA library by complementation of an auxotrophic Escherichia coli: antibodies for orotate decarboxylation. Proc Natl Acad Sci USA. 1994;91:8319-8323
96. Wentworkth P, Datta A, BlakeyD, et al. Towrad antibody-directed "abzyme" prodrug therapy ADAPT: carbamate prodrug activition by a catalytic antiboddy and tis in vitro application to human tumor cell killing. Proc Natl Acad Scid USA. 1996;93(2):799-803
97. HuseWD, Sastry L, Iverson SA, et al. Generation of a large combinational library of the immunoglobulin repertoire in phage lambda. Science. 1989;246:1275-1281
98. Marks JD, Griffiths AD, MaimqvistM, et al. By-passing immunization: building high affinity human antibodies by chain shuffling. Bio / Technology. 1992;10:779-783
99. Cai XH and Garen A. Anti—melanoma antiobdies form melanoma patients immunized with genetically modified antibodies form single— chain Fv fusion phage libravies. Proc Natl Acad Sci USA. 1995;92(14):6537-6541
100. Marks JD, Hoogenboom HR, Bonnert TP, et al. By-passing immunization: human antibodies from V—gene libraries displayed on phage. J Mol Biol. 1991;222:581-597
101. Barbas CF, Kang AS, Lerner RA, et al. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA. 1991;88:7978-7982
102. Kung PC, Goldstein G. Monoclonal antibodies defining distinctive human T cell surface antigens. Science. 1979;206:347-349
103. Van Vauwe JP, DeMey JR and Goossens JD. OKT3 a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol. 1980;124:2708-2713
104. Yun YS, Hargrove ME and Ting C. Hetero-geneity of long-term culture acti- vated killer cells induced by anti-CD3 antibody. J Immunol. 1988;141:1390—1397
105. Weiss A, Imboden J, HArdyK, et al.Annu Rev Immunol. 1986;4:593
106. Nishizuka Y. Science. 1986;4:593
107. Patel MP, Samclson LE and Klausuer RD. Multiple kinases and signal transduction. J Biol Chem. 1987;262:5831-3838
108. Samelson LE, Phillips AF, Lnong ET, et al. Proc Natl Acad Sci USA. 1990;87:4358
109. Boyer C, Auphan N, Luton F, et al. T cell receptor/ CD3 complex internalization following activation of a cytolytic T cell clone: evidence for a protein kinase C-independent staurosporine—sensitive step. Eur J Immunol. 1991;21:1623-1634
110. De Jong R, Brouwer M, Rebel VI, et al. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirments for human cytolytic T- lymphocyte differentiation. Immunol. 1990;70:357-364
111. Gromo G, Geller RL, Inverardi L, et al. Signal reguirements in the step—wise functional maturation of cytotoxic T lymphocytes. Nature. 1987;327:434-436
112. Takai Y, Herrmann SH, Greenstein JL, et al. Requirement of three distinct lymphokines for the induction of cytotoxic T lymphocytes from thymocytes. J Immunol. 1986;137:3494-3500
113. Jung G, Martin DE and Muller—Eberhard HJ. Induction of cytotoxicity in hu- man peripheral blood mononulear cells by monoclonal antibody OKT3. J Immunol. 1987;139:639-644
114. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft regection with OKT3 monoclonal antibody. Transplantation. 1981;32:535—539
115. Hirsch RM, Eckhclonal H, Auchincloss DH, et al. Effects of in vivo admini- stration of anti-T3 monoclonal antibody on T cell function in mice:I.Immunosupression of transplantation response. J Immuno 1988; 140:3766-3772
116. Segal DM, Garrido MA, Prez P, et al. Targeted cytotoxic cells as a novel form of cancer immunotherapy. Mol. Immunol. 1988;25:1099—1103
117. Nitta T, Sato K, yagita H et al. Preliminary trail of specific targeting therapy against malignant glioma. Lancet 1990;335:368—371
118. Perez P, Hoffman RW, Shaw S, et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985;316:354-356
119. VanDijk JSO, Warnaar JDH, Van Eendenbury M, et al. Induction of tumor—cell lysis by bi- specific antibodies recognizing renal— cell carcinoma and CD3 antigen. Int J Cancer 1989;43:344-351
120. Parren PWHI, Warmerdam PAM. Boeije LCM, et al. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. J Immunol. 1992;148:695—701
121. Shalaby MR, Shepard HM, Presta L, et al. Development of humanized bispecific antibodies reactive overexpressing the HER2 protooncogene. J Exp Med. 1992;175;217-225
122. Rodrigues ML, Shalaby MR, Werther W, et al. Engineering a humanized bispecific F(ab')2 P fragment for improved binding to T cells. Int J Cancer. 1992;7:45-56
123. Chamow SM, Zhang DZ. Tang XY, et al. A humanized, bispecific immunodhcsin-antibody that retargets CD3+ effcctors to kill HIV-1-infected cells. J Immunol. 1994;153:4268-4280
124. Allegre ML, Tso Jy, Sattar HA, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol. 1995;155(3): 1544-1555
125. Mu SL, Thompson J, Hu HZ, et al. Expression and characterization of a bivalent chimeric anti-human CD3 single chain antibody. Sacadinvian J Immunol. 1996;43:134-139
126. Horton RM, Hunt HD. Ho SN, et al. Engineering bybrid genes withoutthe use of restriction enzymes: gene splicing by overlap extension. Gene. 1988;77:61-68
127. Laemmli Uk. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685
128．高磊．两株人源性HFRSV单抗可变区基因的克隆、序列分析及表达的研究．博士论文1994
129．胡川闽．抗肝癌单链免疫毒素的基因构建、及其导向作用的实验研究．博士论文1996
130. Marston FAO. The purification of eukaryotic polypcptcdcs synthesized in Eschcrichia coll. Biochemistry J 1986;240: 1-12
131. Chapoval AI, Nelson H, Thibault C, ctal. Anti-Cd3×anti-tumor F(ab′)2bisfunctional antibody activates and rctargcts tumor-infiltrating lym phocytcs. J Immunol 1995; 155(3): 1296-13031
132．韩丽英．抗金属螯合四肽单克隆抗体可变区基因的构建及表达．博士论文，1995